



CONTACT

Shari Annes, 650-888-0902
Investor Relations
sannes@oxigene.com

OXiGENE To Present at LAZARD Healthcare Conference on November 28

WALTHAM, Mass.-- November 26, 2007 -- OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that OXiGENE President and CEO, Dr. Richard Chin, will present at the Lazard Capital Markets Fourth Annual Healthcare Conference at the New York Palace Hotel in New York City on Wednesday, November 28, at 9:30 a.m. EST / 6:30 a.m. PST.

A live and archived webcast of the presentation will be accessible via the Company's website at www.oxigene.com under the Investor Center/ Presentations & Conference Calls section.

About OXiGENE, Inc.

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life-extending and -enhancing medicines to patients.

-- # # # --